JP2017081918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017081918A5 JP2017081918A5 JP2016214165A JP2016214165A JP2017081918A5 JP 2017081918 A5 JP2017081918 A5 JP 2017081918A5 JP 2016214165 A JP2016214165 A JP 2016214165A JP 2016214165 A JP2016214165 A JP 2016214165A JP 2017081918 A5 JP2017081918 A5 JP 2017081918A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- phenyl
- disease
- pyrimidine
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 7
- 208000014644 Brain disease Diseases 0.000 claims 6
- 208000020016 psychiatric disease Diseases 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 230000006735 deficit Effects 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 206010013663 drug dependence Diseases 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000008451 emotion Effects 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010010144 Completed suicide Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000003104 endogenous depression Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000000230 African Trypanosomiasis Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000006740 Aseptic Meningitis Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010065369 Burnout syndrome Diseases 0.000 claims 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010013647 Drowning Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000003863 Marijuana Abuse Diseases 0.000 claims 1
- 206010027201 Meningitis aseptic Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000004221 Multiple Trauma Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000000810 Separation Anxiety Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000029033 Spinal Cord disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 241000223105 Trypanosoma brucei Species 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 230000004594 appetite change Effects 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 201000005105 barbiturate dependence Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000025698 brain inflammatory disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000001843 cannabis dependence Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000037326 chronic stress Effects 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000020595 eating behavior Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000008921 facial expression Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000029080 human African trypanosomiasis Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000010365 information processing Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000011977 language disease Diseases 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 230000007787 long-term memory Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000008013 morphine dependence Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 230000008058 pain sensation Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000025874 separation anxiety disease Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000002612 sleeping sickness Diseases 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 230000003936 working memory Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- -1 2,3-dihydrobenzofuran-5-yl Chemical group 0.000 description 131
- 239000000126 substance Substances 0.000 description 34
- 239000001257 hydrogen Substances 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- DXXHGTWWVTYUIY-UHFFFAOYSA-N 6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3OCCOC3=CC=2)=N1 DXXHGTWWVTYUIY-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- KAPFCJYSHMMHHG-UHFFFAOYSA-N 6-(4-chloro-3-methoxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 KAPFCJYSHMMHHG-UHFFFAOYSA-N 0.000 description 3
- HCMSVNWFFJPWJC-UHFFFAOYSA-N 6-quinolin-6-ylpyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3C=CC=NC3=CC=2)=N1 HCMSVNWFFJPWJC-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 3
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- LQBCVDIPSNMKDD-UHFFFAOYSA-N 6-(1,3-benzodioxol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3OCOC3=CC=2)=N1 LQBCVDIPSNMKDD-UHFFFAOYSA-N 0.000 description 2
- VIDDOIYIHXKWEQ-UHFFFAOYSA-N 6-(2,2-difluoro-1,3-benzodioxol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3OC(F)(F)OC3=CC=2)=N1 VIDDOIYIHXKWEQ-UHFFFAOYSA-N 0.000 description 2
- AZGINHVEMXJOGL-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C3CC3)=CC=2)=N1 AZGINHVEMXJOGL-UHFFFAOYSA-N 0.000 description 2
- KYPSKXAYQTYOFI-UHFFFAOYSA-N 6-(3-chloro-4-pyrrolidin-1-ylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(N3CCCC3)=CC=2)=N1 KYPSKXAYQTYOFI-UHFFFAOYSA-N 0.000 description 2
- QFQHJZKECPZGLZ-UHFFFAOYSA-N 6-(3-chloro-4-pyrrolidin-2-ylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C3NCCC3)=CC=2)=N1 QFQHJZKECPZGLZ-UHFFFAOYSA-N 0.000 description 2
- ANCVBRFECVCVKS-UHFFFAOYSA-N 6-(4-chloro-1,3-benzoxazol-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3OC=NC3=C(Cl)C=2)=N1 ANCVBRFECVCVKS-UHFFFAOYSA-N 0.000 description 2
- SIYCDJHEVASOGW-UHFFFAOYSA-N 6-(4-chloro-3-cyclopropyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(OC3CC3)C(Cl)=CC=2)=N1 SIYCDJHEVASOGW-UHFFFAOYSA-N 0.000 description 2
- HAKPEXMHSQJZGE-UHFFFAOYSA-N 6-(4-chloro-3-propan-2-yloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 HAKPEXMHSQJZGE-UHFFFAOYSA-N 0.000 description 2
- SFEFRQOLESCMSD-UHFFFAOYSA-N 6-(4-tert-butyl-3-chlorophenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(C(C)(C)C)=CC=C1C1=CC(C(O)=O)=NC=N1 SFEFRQOLESCMSD-UHFFFAOYSA-N 0.000 description 2
- DTUYEUHTIOVJOT-UHFFFAOYSA-N 6-(5-chloroquinazolin-7-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3N=CN=CC3=C(Cl)C=2)=N1 DTUYEUHTIOVJOT-UHFFFAOYSA-N 0.000 description 2
- QNLAPYWAQTUSMO-UHFFFAOYSA-N 6-(7-chloro-1,3-benzothiazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3N=CSC3=C(Cl)C=2)=N1 QNLAPYWAQTUSMO-UHFFFAOYSA-N 0.000 description 2
- JEKVAHBUQDMJET-UHFFFAOYSA-N 6-(7-chloro-1,3-benzoxazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3N=COC3=C(Cl)C=2)=N1 JEKVAHBUQDMJET-UHFFFAOYSA-N 0.000 description 2
- WRYMFUKRHGTHBN-UHFFFAOYSA-N 6-(7-chloro-1-benzothiophen-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3C=CSC3=C(Cl)C=2)=N1 WRYMFUKRHGTHBN-UHFFFAOYSA-N 0.000 description 2
- KKQXSKUYVOCSAJ-UHFFFAOYSA-N 6-(7-chloro-2-cyclopropyl-1,3-benzoxazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3N=C(OC3=C(Cl)C=2)C2CC2)=N1 KKQXSKUYVOCSAJ-UHFFFAOYSA-N 0.000 description 2
- ISEPNBNCKBSVBY-UHFFFAOYSA-N 6-(7-chloro-2-methyl-1,3-benzoxazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C=1C(Cl)=C2OC(C)=NC2=CC=1C1=CC(C(O)=O)=NC=N1 ISEPNBNCKBSVBY-UHFFFAOYSA-N 0.000 description 2
- JWGVHCNBKLKNLK-UHFFFAOYSA-N 6-(7-chloro-2-oxo-3h-1,3-benzoxazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3NC(=O)OC3=C(Cl)C=2)=N1 JWGVHCNBKLKNLK-UHFFFAOYSA-N 0.000 description 2
- NEHRDWRJUKTTGJ-UHFFFAOYSA-N 6-(7-chloro-3-methyl-2-oxo-1,3-benzoxazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C=1C(Cl)=C2OC(=O)N(C)C2=CC=1C1=CC(C(O)=O)=NC=N1 NEHRDWRJUKTTGJ-UHFFFAOYSA-N 0.000 description 2
- OQJCQSNSJYSKQM-UHFFFAOYSA-N 6-(7-chloro-3a,7a-dihydro-1h-indol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C3NC=CC3C=2)=N1 OQJCQSNSJYSKQM-UHFFFAOYSA-N 0.000 description 2
- YVEQACWEFQPLKG-UHFFFAOYSA-N 6-(7-chloro-3h-benzimidazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3NC=NC3=C(Cl)C=2)=N1 YVEQACWEFQPLKG-UHFFFAOYSA-N 0.000 description 2
- FNHKPPQGEUDHRF-UHFFFAOYSA-N 6-(8-chloroimidazo[1,2-a]pyridin-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C2=CN3C=CN=C3C(Cl)=C2)=N1 FNHKPPQGEUDHRF-UHFFFAOYSA-N 0.000 description 2
- ZWOQQKKPRINPGY-UHFFFAOYSA-N 6-(8-chloroquinazolin-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3C=NC=NC3=C(Cl)C=2)=N1 ZWOQQKKPRINPGY-UHFFFAOYSA-N 0.000 description 2
- MXBJAXNADZUPNO-UHFFFAOYSA-N 6-(8-chloroquinoxalin-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3N=CC=NC3=C(Cl)C=2)=N1 MXBJAXNADZUPNO-UHFFFAOYSA-N 0.000 description 2
- NGFZWJQXSNGURC-UHFFFAOYSA-N 6-[3-chloro-4-(1-cyclopropyloxyethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1C(C)OC1CC1 NGFZWJQXSNGURC-UHFFFAOYSA-N 0.000 description 2
- IPEAOABYMIDHCR-UHFFFAOYSA-N 6-[3-chloro-4-(1-methoxycyclopropyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1C1(OC)CC1 IPEAOABYMIDHCR-UHFFFAOYSA-N 0.000 description 2
- AITQWQMFPSGQKC-UHFFFAOYSA-N 6-[3-chloro-4-(1-methylcyclopropyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1C1(C)CC1 AITQWQMFPSGQKC-UHFFFAOYSA-N 0.000 description 2
- NOEXYBWFAOICAQ-UHFFFAOYSA-N 6-[3-chloro-4-(1-morpholin-4-ylpropan-2-yloxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1OC(C)CN1CCOCC1 NOEXYBWFAOICAQ-UHFFFAOYSA-N 0.000 description 2
- SNFLLZQLPWPDHF-UHFFFAOYSA-N 6-[3-chloro-4-(1h-imidazol-2-yl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C=3NC=CN=3)=CC=2)=N1 SNFLLZQLPWPDHF-UHFFFAOYSA-N 0.000 description 2
- QLHXNWGOOJWHRP-UHFFFAOYSA-N 6-[3-chloro-4-(1h-pyrrol-2-yl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C=3NC=CC=3)=CC=2)=N1 QLHXNWGOOJWHRP-UHFFFAOYSA-N 0.000 description 2
- IQXRYVHXDWKILP-UHFFFAOYSA-N 6-[3-chloro-4-(3-methyloxetan-3-yl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1C1(C)COC1 IQXRYVHXDWKILP-UHFFFAOYSA-N 0.000 description 2
- ARJDUBLNQNMTBU-UHFFFAOYSA-N 6-[3-chloro-4-(cyclopropanecarbonyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C(=O)C3CC3)=CC=2)=N1 ARJDUBLNQNMTBU-UHFFFAOYSA-N 0.000 description 2
- UALYFQRKTBVXFI-UHFFFAOYSA-N 6-[3-chloro-4-(cyclopropylmethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(CC3CC3)=CC=2)=N1 UALYFQRKTBVXFI-UHFFFAOYSA-N 0.000 description 2
- YBGVQOWGBBFAAT-UHFFFAOYSA-N 6-[3-chloro-4-(cyclopropyloxymethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(COC3CC3)=CC=2)=N1 YBGVQOWGBBFAAT-UHFFFAOYSA-N 0.000 description 2
- XBUMWMDNAUQRRD-UHFFFAOYSA-N 6-[3-chloro-4-(furan-2-yl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C=3OC=CC=3)=CC=2)=N1 XBUMWMDNAUQRRD-UHFFFAOYSA-N 0.000 description 2
- KTSNAFGBKMJBOA-UHFFFAOYSA-N 6-[3-chloro-4-[(cyclopropylamino)methyl]phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(CNC3CC3)=CC=2)=N1 KTSNAFGBKMJBOA-UHFFFAOYSA-N 0.000 description 2
- ZVMSGRHDUPQQGV-UHFFFAOYSA-N 6-[3-chloro-4-[1-(trifluoromethyl)cyclopropyl]phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(=CC=2)C2(CC2)C(F)(F)F)=N1 ZVMSGRHDUPQQGV-UHFFFAOYSA-N 0.000 description 2
- ADTHFFYDPUFSGE-UHFFFAOYSA-N 6-[3-chloro-4-[[cyclopropyl(methyl)amino]methyl]phenyl]pyrimidine-4-carboxylic acid Chemical compound C1CC1N(C)CC(C(=C1)Cl)=CC=C1C1=CC(C(O)=O)=NC=N1 ADTHFFYDPUFSGE-UHFFFAOYSA-N 0.000 description 2
- KLVJYJQPFYHIPX-UHFFFAOYSA-N 6-[3-chloro-4-[cyclopropyl(hydroxy)methyl]phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1C(O)C1CC1 KLVJYJQPFYHIPX-UHFFFAOYSA-N 0.000 description 2
- ZXDKEXDBLUBBCU-UHFFFAOYSA-N 6-[3-chloro-4-[cyclopropyl(methyl)amino]phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1N(C)C1CC1 ZXDKEXDBLUBBCU-UHFFFAOYSA-N 0.000 description 2
- OMVLEVUANYVBNZ-UHFFFAOYSA-N 6-[4-(aziridin-1-ylmethyl)-3-chlorophenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(CN3CC3)=CC=2)=N1 OMVLEVUANYVBNZ-UHFFFAOYSA-N 0.000 description 2
- URMVKRXVAAYVCB-UHFFFAOYSA-N 6-[4-chloro-3-(1,1,1-trifluoropropan-2-yloxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C(F)(F)F)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 URMVKRXVAAYVCB-UHFFFAOYSA-N 0.000 description 2
- JRPORKJOVJJRHR-UHFFFAOYSA-N 6-[4-chloro-3-(2-methylpropoxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OCC(C)C)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 JRPORKJOVJJRHR-UHFFFAOYSA-N 0.000 description 2
- VKUIPVSZEKJXEM-UHFFFAOYSA-N 6-[4-chloro-3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(OC(F)(F)F)C(Cl)=CC=2)=N1 VKUIPVSZEKJXEM-UHFFFAOYSA-N 0.000 description 2
- DAWCOJFZNHWQJJ-UHFFFAOYSA-N 6-pyrazolo[1,5-a]pyridin-5-ylpyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C2=CC3=CC=NN3C=C2)=N1 DAWCOJFZNHWQJJ-UHFFFAOYSA-N 0.000 description 2
- BXJIWHPLUHUMNN-UHFFFAOYSA-N 7-chloro-8-cyclopropyloxy-5h-chromeno[4,3-d]pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=NC=NC(C2=CC=3)=C1COC2=C(Cl)C=3OC1CC1 BXJIWHPLUHUMNN-UHFFFAOYSA-N 0.000 description 2
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 description 2
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HPTAYKQPRBVCCO-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-5-methylpyridine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=C1C1=CC=C(Cl)C(Cl)=C1 HPTAYKQPRBVCCO-UHFFFAOYSA-N 0.000 description 1
- WSKCHSORBUXZCT-UHFFFAOYSA-N 4-(3-chloro-4-cyclopropyloxyphenyl)-5,6-dihydropyrano[3,4-d]pyrimidin-8-one Chemical compound ClC1=CC(C=2C=3CCOC(=O)C=3N=CN=2)=CC=C1OC1CC1 WSKCHSORBUXZCT-UHFFFAOYSA-N 0.000 description 1
- XIFAXVPQDJJCSY-UHFFFAOYSA-N 4-(3-chloro-4-cyclopropyloxyphenyl)-5h-furo[3,4-d]pyrimidin-7-one Chemical compound ClC1=CC(C=2C=3COC(=O)C=3N=CN=2)=CC=C1OC1CC1 XIFAXVPQDJJCSY-UHFFFAOYSA-N 0.000 description 1
- FNAMSGJQIOWTCP-UHFFFAOYSA-N 4-(3-chloro-4-cyclopropyloxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CC3)=CC=2)=C1 FNAMSGJQIOWTCP-UHFFFAOYSA-N 0.000 description 1
- ULKYTVQUDWPDMC-UHFFFAOYSA-N 4-(3-chloro-4-propan-2-yloxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=CC=NC(C(O)=O)=C1 ULKYTVQUDWPDMC-UHFFFAOYSA-N 0.000 description 1
- WOVSMFPKDXPWKT-UHFFFAOYSA-N 4-[3-chloro-4-(trifluoromethoxy)phenyl]pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC(F)(F)F)=CC=2)=C1 WOVSMFPKDXPWKT-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- TVVCSTRAYMERTP-UHFFFAOYSA-N 6-(3-amino-4-chlorophenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(N)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 TVVCSTRAYMERTP-UHFFFAOYSA-N 0.000 description 1
- JAJUIFDFFNEPOK-UHFFFAOYSA-N 6-(3-chloro-4-cyclobutyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CCC3)=CC=2)=N1 JAJUIFDFFNEPOK-UHFFFAOYSA-N 0.000 description 1
- MUQRMMDWZTUCAE-UHFFFAOYSA-N 6-(3-chloro-4-cyclopentyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CCCC3)=CC=2)=N1 MUQRMMDWZTUCAE-UHFFFAOYSA-N 0.000 description 1
- OYYHAOLYRLAJMS-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropyloxyphenyl)-5-(hydroxymethyl)pyrimidine-4-carboxylic acid Chemical compound OCC1=C(C(O)=O)N=CN=C1C(C=C1Cl)=CC=C1OC1CC1 OYYHAOLYRLAJMS-UHFFFAOYSA-N 0.000 description 1
- JMIKKDBJCSHSES-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropyloxyphenyl)-5-methylpyrimidine-4-carboxylic acid Chemical compound CC1=C(C(O)=O)N=CN=C1C(C=C1Cl)=CC=C1OC1CC1 JMIKKDBJCSHSES-UHFFFAOYSA-N 0.000 description 1
- UPKQDTLLVVTZQT-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CC3)=CC=2)=N1 UPKQDTLLVVTZQT-UHFFFAOYSA-N 0.000 description 1
- HCLIGRDEUKEFDN-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropylsulfanylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(SC3CC3)=CC=2)=N1 HCLIGRDEUKEFDN-UHFFFAOYSA-N 0.000 description 1
- RWQLIXPRYQWELW-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropylsulfinylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(=CC=2)S(=O)C2CC2)=N1 RWQLIXPRYQWELW-UHFFFAOYSA-N 0.000 description 1
- WDVUVYNDMVOEDI-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropylsulfonylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(=CC=2)S(=O)(=O)C2CC2)=N1 WDVUVYNDMVOEDI-UHFFFAOYSA-N 0.000 description 1
- PWFZXYHXMKUNLH-UHFFFAOYSA-N 6-(3-chloro-4-methoxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1C1=CC(C(O)=O)=NC=N1 PWFZXYHXMKUNLH-UHFFFAOYSA-N 0.000 description 1
- DFJNJNRBWMZOFO-UHFFFAOYSA-N 6-(3-chloro-4-methylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(C)=CC=C1C1=CC(C(O)=O)=NC=N1 DFJNJNRBWMZOFO-UHFFFAOYSA-N 0.000 description 1
- IJDDVBKPKGOPAS-UHFFFAOYSA-N 6-(3-chloro-4-methylsulfanylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(SC)=CC=C1C1=CC(C(O)=O)=NC=N1 IJDDVBKPKGOPAS-UHFFFAOYSA-N 0.000 description 1
- MJFHBSWQPIUFIM-UHFFFAOYSA-N 6-(3-chloro-4-methylsulfinylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(S(=O)C)=CC=C1C1=CC(C(O)=O)=NC=N1 MJFHBSWQPIUFIM-UHFFFAOYSA-N 0.000 description 1
- SXSWGHPSWXZELW-UHFFFAOYSA-N 6-(3-chloro-4-methylsulfonylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C1=CC(C(O)=O)=NC=N1 SXSWGHPSWXZELW-UHFFFAOYSA-N 0.000 description 1
- DFXWMGMGIACMMR-UHFFFAOYSA-N 6-(3-chloro-4-propan-2-yloxyphenyl)-2-methylpyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=CC(C(O)=O)=NC(C)=N1 DFXWMGMGIACMMR-UHFFFAOYSA-N 0.000 description 1
- WWIJIMDOMQMPAS-UHFFFAOYSA-N 6-(3-chloro-4-propan-2-yloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=CC(C(O)=O)=NC=N1 WWIJIMDOMQMPAS-UHFFFAOYSA-N 0.000 description 1
- FQYVQNFVKIUDMS-UHFFFAOYSA-N 6-(3-chloro-4-propan-2-ylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(C(C)C)=CC=C1C1=CC(C(O)=O)=NC=N1 FQYVQNFVKIUDMS-UHFFFAOYSA-N 0.000 description 1
- MWLAMNVSRJYJEC-UHFFFAOYSA-N 6-(3-chloro-4-pyrrolidin-3-yloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CNCC3)=CC=2)=N1 MWLAMNVSRJYJEC-UHFFFAOYSA-N 0.000 description 1
- NLBJLZWUJAVYMC-UHFFFAOYSA-N 6-(3-chloro-4-pyrrolidin-3-ylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(C3CNCC3)=CC=2)=N1 NLBJLZWUJAVYMC-UHFFFAOYSA-N 0.000 description 1
- MFHQRCJQJVHJNY-UHFFFAOYSA-N 6-(3-fluoro-4-methylphenyl)-2-methylpyrimidine-4-carboxylic acid Chemical compound CC1=NC(C(O)=O)=CC(C=2C=C(F)C(C)=CC=2)=N1 MFHQRCJQJVHJNY-UHFFFAOYSA-N 0.000 description 1
- FMYASDAPHJQSDM-UHFFFAOYSA-N 6-(3-fluoro-4-methylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(F)C(C)=CC=C1C1=CC(C(O)=O)=NC=N1 FMYASDAPHJQSDM-UHFFFAOYSA-N 0.000 description 1
- UHGBZSRMMLGQPU-UHFFFAOYSA-N 6-(3-fluoro-4-propan-2-ylphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(F)C(C(C)C)=CC=C1C1=CC(C(O)=O)=NC=N1 UHGBZSRMMLGQPU-UHFFFAOYSA-N 0.000 description 1
- DKVDSCBUJJIFAV-UHFFFAOYSA-N 6-(4-chloro-2-methyl-1,3-benzoxazol-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=C2OC(C)=NC2=C(Cl)C=C1C1=CC(C(O)=O)=NC=N1 DKVDSCBUJJIFAV-UHFFFAOYSA-N 0.000 description 1
- HTYJPHFKERETNU-UHFFFAOYSA-N 6-(7-chloro-1-benzofuran-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3C=COC3=C(Cl)C=2)=N1 HTYJPHFKERETNU-UHFFFAOYSA-N 0.000 description 1
- UREIJDJVIJFGEI-UHFFFAOYSA-N 6-(7-chloro-1-methyl-3a,7a-dihydroindazol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C2N(C)N=CC2C=C1C1=CC(C(O)=O)=NC=N1 UREIJDJVIJFGEI-UHFFFAOYSA-N 0.000 description 1
- YGXXONBSCPXHLI-UHFFFAOYSA-N 6-(7-chloro-2,3,3a,7a-tetrahydro-1-benzofuran-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C3OCCC3C=2)=N1 YGXXONBSCPXHLI-UHFFFAOYSA-N 0.000 description 1
- ZOPGOFJOTQRURG-UHFFFAOYSA-N 6-(7-chloro-2,3-dihydro-1-benzofuran-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C=3OCCC=3C=2)=N1 ZOPGOFJOTQRURG-UHFFFAOYSA-N 0.000 description 1
- UJWQTZGUQWSJQV-UHFFFAOYSA-N 6-(7-chloro-2-cyclopropyl-1,3-dihydroisoindol-5-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C=3CN(CC=3C=2)C2CC2)=N1 UJWQTZGUQWSJQV-UHFFFAOYSA-N 0.000 description 1
- ZLJVZOGKOUVUKI-UHFFFAOYSA-N 6-(8-chloro-1,2,3,4-tetrahydroquinolin-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3CCCNC3=C(Cl)C=2)=N1 ZLJVZOGKOUVUKI-UHFFFAOYSA-N 0.000 description 1
- IPZUUGDXCXNZRL-UHFFFAOYSA-N 6-(8-chloro-1-methyl-3,4-dihydro-2h-quinolin-6-yl)pyrimidine-4-carboxylic acid Chemical compound C=1C(Cl)=C2N(C)CCCC2=CC=1C1=CC(C(O)=O)=NC=N1 IPZUUGDXCXNZRL-UHFFFAOYSA-N 0.000 description 1
- POTRLNHYXZVNCZ-UHFFFAOYSA-N 6-(8-chloro-3,4-dihydro-2h-chromen-6-yl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C3CCCOC3=C(Cl)C=2)=N1 POTRLNHYXZVNCZ-UHFFFAOYSA-N 0.000 description 1
- PTONQWJCIRQGRK-UHFFFAOYSA-N 6-[3-chloro-4-(1,1,1-trifluoropropan-2-yloxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C(F)(F)F)=CC=C1C1=CC(C(O)=O)=NC=N1 PTONQWJCIRQGRK-UHFFFAOYSA-N 0.000 description 1
- NUJCWQZUTBHBHQ-UHFFFAOYSA-N 6-[3-chloro-4-(1-methoxyethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(C(C)OC)=CC=C1C1=CC(C(O)=O)=NC=N1 NUJCWQZUTBHBHQ-UHFFFAOYSA-N 0.000 description 1
- GFLIQUZUDSEYEP-UHFFFAOYSA-N 6-[3-chloro-4-(2-piperidin-1-ylethoxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OCCN3CCCCC3)=CC=2)=N1 GFLIQUZUDSEYEP-UHFFFAOYSA-N 0.000 description 1
- NLGSLISVAVLWMR-UHFFFAOYSA-N 6-[3-chloro-4-(cyclopropylamino)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(NC3CC3)=CC=2)=N1 NLGSLISVAVLWMR-UHFFFAOYSA-N 0.000 description 1
- GCKCDGAFVFDNGW-UHFFFAOYSA-N 6-[3-chloro-4-(methoxymethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(COC)=CC=C1C1=CC(C(O)=O)=NC=N1 GCKCDGAFVFDNGW-UHFFFAOYSA-N 0.000 description 1
- HSGCDKCENGBLPX-UHFFFAOYSA-N 6-[3-chloro-4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC(F)(F)F)=CC=2)=N1 HSGCDKCENGBLPX-UHFFFAOYSA-N 0.000 description 1
- ZFRNQYCWYGPUFJ-UHFFFAOYSA-N 6-[3-chloro-4-[(dimethylamino)methyl]phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(CN(C)C)=CC=C1C1=CC(C(O)=O)=NC=N1 ZFRNQYCWYGPUFJ-UHFFFAOYSA-N 0.000 description 1
- DDUMPYGCUZWKAJ-UHFFFAOYSA-N 6-[4-chloro-3-(2-morpholin-4-ylethoxy)phenyl]-n-pyridin-3-ylpyrimidine-4-carboxamide Chemical compound ClC1=CC=C(C=2N=CN=C(C=2)C(=O)NC=2C=NC=CC=2)C=C1OCCN1CCOCC1 DDUMPYGCUZWKAJ-UHFFFAOYSA-N 0.000 description 1
- GJRNNZOXIKKPSD-UHFFFAOYSA-N 6-[4-chloro-3-(oxolan-3-yloxy)phenyl]-n-pyridin-3-ylpyrimidine-4-carboxamide Chemical compound ClC1=CC=C(C=2N=CN=C(C=2)C(=O)NC=2C=NC=CC=2)C=C1OC1CCOC1 GJRNNZOXIKKPSD-UHFFFAOYSA-N 0.000 description 1
- SPEDYHMZKJOPOZ-UHFFFAOYSA-N 6-[4-chloro-3-(oxolan-3-yloxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(OC3COCC3)C(Cl)=CC=2)=N1 SPEDYHMZKJOPOZ-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- WTHDCTVUOUNROI-UHFFFAOYSA-N ClC=1C=C(C=CC1NC1CC1)C1=CC(=NC=N1)C(=O)O.ClC=1C=C(C=CC1CN(C)C)C1=CC(=NC=N1)C(=O)O Chemical compound ClC=1C=C(C=CC1NC1CC1)C1=CC(=NC=N1)C(=O)O.ClC=1C=C(C=CC1CN(C)C)C1=CC(=NC=N1)C(=O)O WTHDCTVUOUNROI-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004540 benzothiazol-5-yl group Chemical group S1C=NC2=C1C=CC(=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VRJCJIVIECVPBI-UHFFFAOYSA-N methyl 6-(3-chloro-4-methoxyphenyl)pyrimidine-4-carboxylate Chemical compound C1=NC(C(=O)OC)=CC(C=2C=C(Cl)C(OC)=CC=2)=N1 VRJCJIVIECVPBI-UHFFFAOYSA-N 0.000 description 1
- VILJUHIEKNITDI-UHFFFAOYSA-N methyl 6-(3-chloro-4-methylphenyl)pyrimidine-4-carboxylate Chemical compound C1=NC(C(=O)OC)=CC(C=2C=C(Cl)C(C)=CC=2)=N1 VILJUHIEKNITDI-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UPSNGAGFVWTGTA-UHFFFAOYSA-N n-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC(C=2C=C(Cl)C(OC3CC3)=CC=2)=NC=N1 UPSNGAGFVWTGTA-UHFFFAOYSA-N 0.000 description 1
- NHNNNQMEILXDMV-UHFFFAOYSA-N n-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]-4-fluorobenzenesulfonamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=CC(C=2C=C(Cl)C(OC3CC3)=CC=2)=NC=N1 NHNNNQMEILXDMV-UHFFFAOYSA-N 0.000 description 1
- AJZPXSIAEFVSBW-UHFFFAOYSA-N n-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]benzenesulfonamide Chemical compound ClC1=CC(C=2N=CN=C(NS(=O)(=O)C=3C=CC=CC=3)C=2)=CC=C1OC1CC1 AJZPXSIAEFVSBW-UHFFFAOYSA-N 0.000 description 1
- YOVZPKYPJSILPO-UHFFFAOYSA-N n-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]cyclopropanesulfonamide Chemical compound ClC1=CC(C=2N=CN=C(NS(=O)(=O)C3CC3)C=2)=CC=C1OC1CC1 YOVZPKYPJSILPO-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161528998P | 2011-08-30 | 2011-08-30 | |
| US61/528,998 | 2011-08-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528519A Division JP6038151B2 (ja) | 2011-08-30 | 2012-08-28 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017081918A JP2017081918A (ja) | 2017-05-18 |
| JP2017081918A5 true JP2017081918A5 (enExample) | 2017-06-29 |
| JP6330011B2 JP6330011B2 (ja) | 2018-05-23 |
Family
ID=47756807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528519A Active JP6038151B2 (ja) | 2011-08-30 | 2012-08-28 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
| JP2016214165A Active JP6330011B2 (ja) | 2011-08-30 | 2016-11-01 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528519A Active JP6038151B2 (ja) | 2011-08-30 | 2012-08-28 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9981918B2 (enExample) |
| EP (2) | EP2750677B1 (enExample) |
| JP (2) | JP6038151B2 (enExample) |
| KR (2) | KR102027287B1 (enExample) |
| CN (1) | CN106518845B (enExample) |
| AR (1) | AR087710A1 (enExample) |
| AU (2) | AU2012302144B2 (enExample) |
| BR (1) | BR112014004741B1 (enExample) |
| CA (1) | CA2844128C (enExample) |
| CL (1) | CL2014000447A1 (enExample) |
| CO (1) | CO7020907A2 (enExample) |
| DK (1) | DK2750677T3 (enExample) |
| EA (2) | EA032526B1 (enExample) |
| ES (2) | ES2765805T3 (enExample) |
| HR (1) | HRP20170928T1 (enExample) |
| HU (1) | HUE034802T2 (enExample) |
| IL (2) | IL231270A (enExample) |
| MX (2) | MX364378B (enExample) |
| MY (1) | MY166890A (enExample) |
| PE (1) | PE20142081A1 (enExample) |
| PH (2) | PH12017502049A1 (enExample) |
| PL (1) | PL2750677T3 (enExample) |
| PT (1) | PT2750677T (enExample) |
| SG (1) | SG2014012926A (enExample) |
| SI (1) | SI2750677T1 (enExample) |
| TW (2) | TWI592400B (enExample) |
| WO (1) | WO2013033085A1 (enExample) |
| ZA (1) | ZA201401097B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110092266A (ko) | 2008-08-04 | 2011-08-17 | 씨에이치디아이 파운데이션, 인코포레이티드 | 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법 |
| MY166890A (en) * | 2011-08-30 | 2018-07-24 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| ES2972419T3 (es) | 2012-04-05 | 2024-06-12 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos |
| WO2015047982A2 (en) | 2013-09-26 | 2015-04-02 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9938252B2 (en) | 2013-09-26 | 2018-04-10 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| GB201322512D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN106061944A (zh) * | 2014-01-24 | 2016-10-26 | 普渡制药公司 | 吡啶类和嘧啶类物质及其用途 |
| JP2017520610A (ja) * | 2014-07-17 | 2017-07-27 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | Ｈｉｖ関連障害を治療するための方法及び組成物 |
| AU2016215432B2 (en) | 2015-02-02 | 2020-07-30 | Valo Early Discovery, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
| AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
| KR20180002730A (ko) * | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| AU2016258188B2 (en) * | 2015-05-07 | 2021-08-26 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| CN110381963A (zh) | 2016-10-13 | 2019-10-25 | 朱诺治疗学股份有限公司 | 涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物 |
| US11173156B2 (en) * | 2019-06-11 | 2021-11-16 | Chdi Foundation, Inc. | Solid forms of a kynurenine-3-monooxygenase inhibitor |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| KR20230054685A (ko) | 2020-08-06 | 2023-04-25 | 씨에이치디아이 파운데이션, 인코포레이티드 | 헌팅틴 단백질 이미징을 위한 헤테로바이아릴 화합물 및 이미징제 |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707560A (en) | 1970-10-05 | 1972-12-26 | Pfizer | Certain 4-amino-6-aryl-pyrimidines |
| US3908012A (en) | 1970-10-05 | 1975-09-23 | Pfizer | Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators |
| FR2204406A1 (en) | 1972-10-26 | 1974-05-24 | Delalande Sa | 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc. |
| US3950525A (en) | 1973-06-19 | 1976-04-13 | Pfizer Inc. | Relaxation of smooth muscle in a mammal |
| US3935202A (en) | 1974-03-18 | 1976-01-27 | American Home Products Corporation | 3-(4-biphenylylcarbonyl)propionamido cephalosporin derivatives |
| US4634689A (en) | 1985-10-31 | 1987-01-06 | Schering Corporation | Phosphinylalkanoyl imino acids |
| DE3609596A1 (de) | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| WO1988003136A1 (fr) | 1986-10-27 | 1988-05-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de piperazine et leur utilisation medicinale |
| ZW21687A1 (en) | 1986-12-12 | 1988-07-20 | Hoffmann La Roche | Triazine derivatives |
| GB8629711D0 (en) * | 1986-12-12 | 1987-01-21 | Hoffmann La Roche | Triazine derivatives |
| JPH01113377A (ja) | 1987-10-23 | 1989-05-02 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
| MX16687A (es) | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
| US5102904A (en) | 1989-12-08 | 1992-04-07 | American Cyanamid Company | N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas |
| AU644159B2 (en) | 1990-05-17 | 1993-12-02 | Novartis Ag | 2-anilino-4-cyanopyrimidine derivatives |
| DE4103695A1 (de) | 1991-02-07 | 1992-08-13 | Basf Ag | Oximether und diese enthaltende fungizide |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| JPH0741459A (ja) | 1993-07-29 | 1995-02-10 | Sumitomo Pharmaceut Co Ltd | 新規エラスターゼ阻害剤 |
| EP0656348B1 (de) | 1993-12-03 | 2000-05-03 | F. Hoffmann-La Roche Ag | Essigsäurederivate als Arzneimittel |
| US5338739A (en) | 1994-03-10 | 1994-08-16 | Hoechst-Roussel Pharmaceuticals Inc. | (Pyrrolidinyl)phenyl carbamates, compositions and use |
| DE4430639A1 (de) | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten |
| FR2732017B1 (fr) | 1995-03-21 | 2000-09-22 | Inst Nat Sante Rech Med | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
| EP0861239B1 (de) | 1995-11-17 | 2003-02-12 | Bayer CropScience AG | Biphenylether-oxazoline und ihre verwendung als schädlingsbekämpfungsmittel |
| PL327494A1 (en) | 1995-12-22 | 1998-12-21 | Warner Lambert Co | Aromatic keto-carboxylic acids and their derivatives as inhibitors of matrix metalloproteinases |
| DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| WO1998009940A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| MXPA99001974A (es) | 1996-12-09 | 2002-03-27 | Warner Lambert Co | Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular. |
| DE69727695T2 (de) | 1996-12-17 | 2005-02-10 | Warner-Lambert Co. Llc | Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung |
| WO1998035967A2 (en) | 1997-02-18 | 1998-08-20 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
| PL335235A1 (en) | 1997-02-19 | 2000-04-10 | Berlex Lab | N-heterocyclic derivatives as nos inhibitors |
| US5925639A (en) | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
| AU9663798A (en) | 1997-10-06 | 1999-04-27 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| AU1110799A (en) | 1997-10-29 | 1999-05-17 | Warner-Lambert Company | Method of inhibiting metastases of cancer cells |
| HUP0100427A3 (en) | 1997-12-23 | 2002-11-28 | Warner Lambert Co | Ace inhibitor-mmp inhibitor combinations |
| US6169103B1 (en) | 1998-03-03 | 2001-01-02 | Warner-Lambert | Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| HUP0103714A3 (en) | 1998-05-11 | 2003-05-28 | Takeda Pharmaceutical | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity, medicaments containing them and their use |
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| DE69912823T2 (de) | 1998-09-25 | 2004-09-23 | Astrazeneca Ab | Benzamid-derivate und ihre verwendung als cytokine inhibitoren |
| JP4183350B2 (ja) | 1998-10-28 | 2008-11-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェニルピロリジノン誘導体 |
| US6541521B1 (en) | 1999-07-12 | 2003-04-01 | Warner-Lambert Company | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| CA2389208A1 (en) | 1999-10-29 | 2001-05-10 | Takeda Chemical Industries, Ltd. | Process for the preparation of oxyiminoalkanoic acid derivatives |
| AU1303201A (en) | 1999-11-10 | 2001-06-06 | Takeda Chemical Industries Ltd. | Alkoxyiminoalkanoic acid derivatives |
| CA2390932A1 (en) | 1999-11-10 | 2001-05-17 | Takeda Chemical Industries, Ltd. | Body weight gain inhibitors |
| GB0003671D0 (en) | 2000-02-17 | 2000-04-05 | Univ Cardiff | Diphenyl-substituted lower alkanes |
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| WO2002040458A1 (en) | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| US20040077557A1 (en) | 2000-12-21 | 2004-04-22 | Sulejman Ali | Macrolide antibiotics |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| JP2002241358A (ja) | 2001-02-15 | 2002-08-28 | Nippon Soda Co Ltd | オキシム基を有する化合物及び殺虫・殺ダニ剤 |
| AR035858A1 (es) * | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| WO2002098840A1 (en) | 2001-06-04 | 2002-12-12 | Eisai Co., Ltd. | Carboxylic acid derivative and medicine comprising salt or ester of the same |
| WO2002100332A2 (en) | 2001-06-08 | 2002-12-19 | Cytokine Pharmasciences, Inc. | Isoxazoline compounds having mif antagonist activity |
| US6552188B2 (en) | 2001-06-29 | 2003-04-22 | Kowa Co., Ltd. | Unsymmetrical cyclic diamine compound |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| ATE396186T1 (de) | 2001-10-04 | 2008-06-15 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| AU2002359714B2 (en) | 2001-12-18 | 2006-12-21 | Merck Sharp & Dohme Corp. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| JP2005535710A (ja) | 2002-08-09 | 2005-11-24 | トランス テック ファーマ，インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
| WO2004026833A1 (ja) | 2002-09-20 | 2004-04-01 | Takeda Pharmaceutical Company Limited | 環状アミン化合物、その製造法および用途 |
| AU2003280558A1 (en) | 2002-10-11 | 2004-05-04 | Kowa Co., Ltd. | Method for treatment of cancer |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| AU2003293129B2 (en) | 2002-11-27 | 2009-03-12 | Incyte Holdings Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| CA2510298A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
| EP1581493A1 (en) | 2002-12-30 | 2005-10-05 | Eli Lilly And Company | Factor xa inhibitors |
| US20060293339A1 (en) | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
| AU2003902860A0 (en) * | 2003-06-06 | 2003-06-26 | Daicel Chemical Industries, Ltd | Benzimidazole compounds |
| CN1566065A (zh) | 2003-06-27 | 2005-01-19 | 中国医学科学院药物研究所 | α位杂原子取代的γ芳基丁本酮酸衍生物及其制法和其药物组合物与用途 |
| SE0301963D0 (sv) | 2003-07-02 | 2003-07-02 | Astrazeneca Ab | New compounds |
| JP2007500128A (ja) | 2003-07-25 | 2007-01-11 | アムジエン・インコーポレーテツド | 置換複素環式化合物及び使用方法 |
| US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| GB0323581D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Novel compounds |
| US20070099938A1 (en) | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
| WO2005042498A2 (en) | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
| EP1715867A4 (en) | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| EP1727542A4 (en) | 2004-03-26 | 2009-08-05 | Cytokine Pharmasciences Inc | COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE, AND METHODS OF USE FOR INHIBITING MACROPHAGE MIGRATION INHIBITION FACTOR |
| EP2332940B1 (en) | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| WO2006000371A2 (en) | 2004-06-28 | 2006-01-05 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as 11beta-hsd1 inhibitors |
| EP1783116B1 (en) | 2004-08-27 | 2009-08-26 | Astellas Pharma Inc. | 2-phenylpyridine derivative |
| WO2006021458A2 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| CA2588633A1 (en) | 2004-12-07 | 2006-06-15 | Toyama Chemical Co., Ltd. | Novel anthranilic acid derivative or salt thereof |
| US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| BRPI0608581A2 (pt) | 2005-03-14 | 2010-01-19 | Transtech Pharma Inc | derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase |
| CN103173402A (zh) | 2005-06-07 | 2013-06-26 | 洛克菲勒大学 | 胰腺β细胞增殖的刺激 |
| EP2388263A1 (en) | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| WO2007017289A2 (en) | 2005-08-10 | 2007-02-15 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
| US20070060573A1 (en) | 2005-08-10 | 2007-03-15 | Lars Wortmann | Acyltryptophanols |
| US20090221547A1 (en) | 2005-08-23 | 2009-09-03 | Irm Llc | Immunosuppressant Compounds and Compositions |
| TW200745055A (en) | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| EP1960367A2 (en) | 2005-12-05 | 2008-08-27 | Boehringer Ingelheim International GmbH | Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors |
| JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| WO2007087637A2 (en) | 2006-01-26 | 2007-08-02 | Washington State University Research Foundation | Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| ES2303758B1 (es) * | 2006-02-20 | 2009-08-13 | Laboratorios Almirall S.A. | Nuevos derivados de piridin-3-amina. |
| MX2008010646A (es) * | 2006-02-24 | 2008-10-14 | Astellas Pharma Inc | Agente para tratar o prevenir ulcera digestiva. |
| JP2007230963A (ja) | 2006-03-03 | 2007-09-13 | Daiso Co Ltd | ２，４−ジ置換ピリジンの製造法 |
| BRPI0713350B1 (pt) | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| CL2007002315A1 (es) | 2006-08-10 | 2008-02-22 | Glaxo Group Ltd | Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable. |
| EP2054397B1 (en) | 2006-08-16 | 2015-10-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
| EP2054056A4 (en) | 2006-08-16 | 2010-08-25 | J David Gladstone Inst A Testa | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE |
| EP2065369A4 (en) | 2006-08-23 | 2011-12-28 | Astellas Pharma Inc | UREA CONNECTION OR SALT THEREOF |
| ATE532770T1 (de) | 2006-09-05 | 2011-11-15 | Kyowa Hakko Kirin Co Ltd | Imidazolderivat |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US20080077419A1 (en) | 2006-09-27 | 2008-03-27 | Santiago Pamela M | System And Method For Training Employees Of An Organization To Align Their Job Activities To Achieving The Organization's Strategic Objectives |
| US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| US8044209B2 (en) | 2006-10-12 | 2011-10-25 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| WO2008095852A1 (en) | 2007-02-08 | 2008-08-14 | Respiratorius Ab | Bronchorelaxing arylamides |
| JP2008266634A (ja) * | 2007-03-29 | 2008-11-06 | Sumitomo Chemical Co Ltd | 化合物、光電変換素子及び光電気化学電池 |
| US20100101643A1 (en) * | 2007-03-29 | 2010-04-29 | Sumitomo Chemical Company, Limited | Compound, photoelectric converter and photoelectrochemical cell |
| JP2010523579A (ja) | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Ｃｆｔｒ阻害剤化合物およびそれらの使用 |
| EP2002834A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| PE20091309A1 (es) | 2007-12-21 | 2009-09-30 | Astrazeneca Ab | Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| JP2009280521A (ja) | 2008-05-22 | 2009-12-03 | Daiso Co Ltd | ２，４−ジ置換ピリジンの製造法 |
| JP2011184298A (ja) | 2008-06-02 | 2011-09-22 | Sanwa Kagaku Kenkyusho Co Ltd | 新規化合物及びその医薬用途 |
| US20110118262A1 (en) | 2008-07-08 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors |
| US20110230428A1 (en) | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| MX2010014337A (es) | 2008-07-25 | 2011-02-15 | Lundbeck & Co As H | Derivados de adamantil diamida y usos de los mismos. |
| KR20110092266A (ko) * | 2008-08-04 | 2011-08-17 | 씨에이치디아이 파운데이션, 인코포레이티드 | 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법 |
| WO2010017132A1 (en) | 2008-08-04 | 2010-02-11 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| GB0815369D0 (en) * | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| JP5587784B2 (ja) | 2008-10-15 | 2014-09-10 | キッセイ薬品工業株式会社 | 縮合複素環誘導体及びその医薬用途 |
| EP2340243B1 (en) * | 2008-10-17 | 2014-10-08 | Boehringer Ingelheim International GmbH | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| WO2010052448A2 (en) * | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
| KR20110091537A (ko) * | 2008-11-13 | 2011-08-11 | 바이엘 크롭사이언스 아게 | 살진균제로서의 치환 (피리딜)-아지닐아민 유도체 |
| NZ593473A (en) * | 2009-01-12 | 2013-02-22 | Pfizer Ltd | Sulfonamide derivatives |
| WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| TW201040166A (en) * | 2009-04-07 | 2010-11-16 | Astrazeneca Ab | Isoxazol-3(2H)-one analogs as therapeutic agents |
| EA020017B1 (ru) * | 2009-04-30 | 2014-08-29 | Новартис Аг | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ |
| US20120041009A1 (en) | 2009-05-18 | 2012-02-16 | Sumitomo Chemical Company, Limited | Pyrimidine compound and its use in pest control |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| PH12012500713A1 (en) | 2009-10-14 | 2012-11-26 | Merck Sharp & Dohme | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2490530A4 (en) | 2009-10-22 | 2014-01-22 | Univ Washington | COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| US8946197B2 (en) | 2009-11-16 | 2015-02-03 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| US8883785B2 (en) | 2010-01-25 | 2014-11-11 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP5826773B2 (ja) | 2010-02-27 | 2015-12-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ビスアリール−結合アリールトリアゾロン及びその用途 |
| CN102985418B (zh) | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| KR20130056345A (ko) | 2010-09-17 | 2013-05-29 | 퍼듀 퍼머 엘피 | 피리딘 화합물 및 그의 용도 |
| EP2796456A1 (en) | 2010-12-09 | 2014-10-29 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
| HK1198619A1 (en) | 2011-07-28 | 2015-05-22 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| MY166890A (en) * | 2011-08-30 | 2018-07-24 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| ES2972419T3 (es) | 2012-04-05 | 2024-06-12 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos |
| US9938252B2 (en) | 2013-09-26 | 2018-04-10 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2015047982A2 (en) | 2013-09-26 | 2015-04-02 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP2017520610A (ja) | 2014-07-17 | 2017-07-27 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | Ｈｉｖ関連障害を治療するための方法及び組成物 |
-
2012
- 2012-08-28 MY MYPI2014000536A patent/MY166890A/en unknown
- 2012-08-28 WO PCT/US2012/052648 patent/WO2013033085A1/en not_active Ceased
- 2012-08-28 JP JP2014528519A patent/JP6038151B2/ja active Active
- 2012-08-28 HR HRP20170928TT patent/HRP20170928T1/hr unknown
- 2012-08-28 MX MX2014002460A patent/MX364378B/es active IP Right Grant
- 2012-08-28 PH PH12017502049A patent/PH12017502049A1/en unknown
- 2012-08-28 EP EP12828501.2A patent/EP2750677B1/en active Active
- 2012-08-28 PE PE2014000264A patent/PE20142081A1/es not_active Application Discontinuation
- 2012-08-28 ES ES17161699T patent/ES2765805T3/es active Active
- 2012-08-28 CA CA2844128A patent/CA2844128C/en active Active
- 2012-08-28 AU AU2012302144A patent/AU2012302144B2/en active Active
- 2012-08-28 MX MX2019000857A patent/MX382065B/es unknown
- 2012-08-28 HU HUE12828501A patent/HUE034802T2/en unknown
- 2012-08-28 SG SG2014012926A patent/SG2014012926A/en unknown
- 2012-08-28 EA EA201790406A patent/EA032526B1/ru unknown
- 2012-08-28 BR BR112014004741-3A patent/BR112014004741B1/pt active IP Right Grant
- 2012-08-28 PH PH1/2014/500371A patent/PH12014500371A1/en unknown
- 2012-08-28 PL PL12828501T patent/PL2750677T3/pl unknown
- 2012-08-28 KR KR1020147003968A patent/KR102027287B1/ko active Active
- 2012-08-28 DK DK12828501.2T patent/DK2750677T3/en active
- 2012-08-28 EA EA201490277A patent/EA027451B1/ru unknown
- 2012-08-28 CN CN201610973673.4A patent/CN106518845B/zh active Active
- 2012-08-28 EP EP17161699.8A patent/EP3243515B1/en active Active
- 2012-08-28 PT PT128285012T patent/PT2750677T/pt unknown
- 2012-08-28 ES ES12828501.2T patent/ES2629194T3/es active Active
- 2012-08-28 KR KR1020197028064A patent/KR102181011B1/ko active Active
- 2012-08-28 US US14/241,374 patent/US9981918B2/en active Active
- 2012-08-28 SI SI201230984T patent/SI2750677T1/sl unknown
- 2012-08-29 TW TW101131294A patent/TWI592400B/zh active
- 2012-08-29 AR ARP120103185A patent/AR087710A1/es unknown
- 2012-08-29 TW TW106113095A patent/TWI617308B/zh active
-
2014
- 2014-02-12 ZA ZA2014/01097A patent/ZA201401097B/en unknown
- 2014-02-25 CL CL2014000447A patent/CL2014000447A1/es unknown
- 2014-02-28 CO CO14042582A patent/CO7020907A2/es unknown
- 2014-03-02 IL IL231270A patent/IL231270A/en active IP Right Grant
-
2016
- 2016-11-01 JP JP2016214165A patent/JP6330011B2/ja active Active
-
2017
- 2017-05-23 AU AU2017203454A patent/AU2017203454B2/en active Active
- 2017-08-08 IL IL253911A patent/IL253911A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017081918A5 (enExample) | ||
| JP6118927B2 (ja) | Ｋｖ３阻害剤として有用なヒダントイン誘導体 | |
| JP6538266B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールスルファミド誘導体化合物及びこれを含有する薬剤学的組成物（１，３，４−Ｏｘａｄｉａｚｏｌｅ Ｓｕｌｆａｍｉｄｅ Ｄｅｒｉｖａｔｉｖｅ Ｃｏｍｐｏｕｎｄｓ ａｓ Ｈｉｓｔｏｎｅ Ｄｅａｃｅｔｙｌａｓｅ ６ Ｉｎｈｉｂｉｔｏｒ， ａｎｄ ｔｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐｏｓｉｔｉｏｎ Ｃｏｍｐｒｉｓｉｎｇ ｔｈｅ ｓａｍｅ） | |
| EP1492771B1 (de) | Chinolin- und isochinolin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer | |
| AU2004217977B2 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
| EP1730119B1 (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
| EP2900642B1 (en) | Substituted sulfonamide compounds | |
| CN106518845B (zh) | 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 | |
| US20110281873A1 (en) | Pyrimidine Compounds and Methods of Making and Using Same | |
| JP2007523152A5 (enExample) | ||
| JP2018108997A5 (enExample) | ||
| EA021126B1 (ru) | Замещенные изохинолиноны и хинализолиноны | |
| DK2953943T3 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| JP2010539180A (ja) | ヒスタミン３拮抗薬としてのイソキノリニルおよびイソインドリニル誘導体 | |
| EP1751139A2 (en) | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | |
| TW593285B (en) | Phenylpyridazine compounds and medicines containing the same | |
| TW200403058A (en) | Heterocyclo inhibitors of potassium channel function | |
| MX2011002042A (es) | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. | |
| BG64849B1 (bg) | Производни на ацил-пиперазинил-пиримидини, тяхното получаване и използването им като лекарствени средства | |
| EA010265B1 (ru) | Производные пиримидина для использования в качестве лигандов ваниллоидных рецепторов и их применение для терапии боли | |
| JP2019502696A (ja) | Ｋｖ３チャネルのヒダントインモジュレーター | |
| JP2018519253A5 (enExample) | ||
| JP2009542804A (ja) | 不整脈の治療のためのイソインドリン誘導体 | |
| KR20090071666A (ko) | Ｍａｐｋ／ｅｒｋ 키나아제 억제제 | |
| JP7664642B2 (ja) | 化合物およびｍｉｆ阻害剤としての用途 |